Enanta initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Ed Arce initiated coverage of Enanta Pharmaceuticals with a Buy rating and $56 price target. The analyst says that while the company’s COVID program draws interest, his positive thesis relies on its RSV program. RSV is a large, untapped opportunity that affects vulnerable patients, Arce tells investors in a research note.